ImmunoGen Inc. [NASDAQ: IMGN] stock went on an upward path that rose over 0.33% on Monday, amounting to a one-week price increase of more than 10.83%. The company report on December 6, 2020 that ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting.
Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session.
Preclinical Combination Data in Relapsed/Refractory AML Support Further Evaluation of Triplet; Trial in Progress Poster for Phase 1b/2 Study Presented.
Over the last 12 months, IMGN stock rose by 56.27%. The one-year ImmunoGen Inc. stock forecast points to a potential upside of 31.44. The average equity rating for IMGN stock is currently 2.10, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.09 billion, with 187.53 million shares outstanding and 175.76 million shares in the current float. Compared to the average trading volume of 2.73M shares, IMGN stock reached a trading volume of 3199203 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ImmunoGen Inc. [IMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMGN shares is $8.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMGN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 26, 2020. The new note on the price target was released on October 02, 2020, representing the official price target for ImmunoGen Inc. stock. On December 17, 2019, analysts increased their price target for IMGN shares from 5 to 9.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.34, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 11.97.
IMGN Stock Performance Analysis:
ImmunoGen Inc. [IMGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.83. With this latest performance, IMGN shares dropped by -0.17% in over the last four-week period, additionally plugging by 30.45% over the last 6 months – not to mention a rise of 56.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 62.48, with the RSI for the last a single of trading hit 64.09, and the three-weeks RSI is set at 60.51 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 5.34, while it was recorded at 5.81 for the last single week of trading, and 4.37 for the last 200 days.
Insight into ImmunoGen Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -85.98. ImmunoGen Inc.’s Net Margin is presently recorded at -126.57.
Return on Total Capital for IMGN is now -60.07, given the latest momentum, and Return on Invested Capital for the company is -125.91. Additionally, IMGN Total Debt to Total Capital is recorded at 202.50, with Total Debt to Total Assets ending up at 63.92.
Reflecting on the efficiency of the workforce at the company, ImmunoGen Inc. [IMGN] managed to generate an average of -$1,388,440 per employee. Receivables Turnover for the company is 4.19 with a Total Asset Turnover recorded at a value of 0.31.ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
IMGN Stock EPS
With the latest financial reports released by the company, ImmunoGen Inc. posted 0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 160.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMGN.
ImmunoGen Inc. [IMGN] Insider Position Details
There are presently around $858 million, or 76.40% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 23,080,128, which is approximately -0.993% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 14,188,530 shares of the stock with an approximate value of $85.7 million in IMGN stocks shares; and BLACKROCK INC., currently with $82.95 million in IMGN stock with ownership of nearly -4.918% of the company’s market capitalization.
Positions in ImmunoGen Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 72 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 19,516,510 shares. Additionally, 101 investors decreased positions by around 16,567,831 shares, while 41 investors held positions by with 105,920,342 shares. The mentioned changes placed institutional holdings at 142,004,683 shares, according to the latest SEC report filing. IMGN stock had 23 new institutional investments in for a total of 8,419,038 shares, while 32 institutional investors sold positions of 3,801,173 shares during the same period.